

# Gerald P Linette

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/549230/publications.pdf>

Version: 2024-02-01

29  
papers

5,568  
citations

471509

17  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

9981  
citing authors

#	ARTICLE	IF	CITATIONS
1	A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. <i>Science</i> , 2015, 348, 803-808.	12.6	1,139
2	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	10.7	1,034
3	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. <i>Blood</i> , 2013, 122, 863-871.	1.4	932
4	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568.	10.7	827
5	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nature Medicine</i> , 2019, 25, 454-461.	30.7	466
6	pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. <i>Genome Medicine</i> , 2016, 8, 11.	8.2	350
7	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. <i>Neuro-Oncology</i> , 2018, 20, 1429-1438.	1.2	197
8	IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. <i>Journal of Clinical Investigation</i> , 2013, 123, 3383-3394.	8.2	137
9	CAR T-Cell Therapies in Glioblastoma: A First Look. <i>Clinical Cancer Research</i> , 2018, 24, 535-540.	7.0	103
10	Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1370-1372.	0.7	54
11	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. <i>Nature Communications</i> , 2021, 12, 4365.	12.8	53
12	Neoantigen Vaccines Pass the Immunogenicity Test. <i>Trends in Molecular Medicine</i> , 2017, 23, 869-871.	6.7	45
13	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 23662-23670.	7.1	40
14	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1098-1106.	7.0	32
15	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage III-IV melanoma. <i>Melanoma Research</i> , 2018, 28, 44-51.	1.2	31
16	Management Controversies in Head and Neck Melanoma. <i>JAMA Facial Plastic Surgery</i> , 2017, 19, 53-62.	2.1	19
17	Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. , 2021, 9, e003148.		18
18	Biomarkers in melanoma: Stage III and IV disease. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 65-74.	3.1	17

#	ARTICLE	IF	CITATIONS
19	Dendritic cell-based vaccines. <i>Oncolmmunology</i> , 2013, 2, e26512.	4.6	15
20	<scp>TRPM1</scp> (melastatin) expression is an independent predictor of overall survival in clinical <scp>AJCC</scp> stage I and <scp>II</scp> melanoma patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 328-337.	1.3	13
21	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1780-1788.	2.8	12
22	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 192-192.	1.6	11
23	Amino-Terminal Extended Peptide Single-Chain Trimers Are Potent Synthetic Agonists for Memory Human CD8+ T Cells. <i>Journal of Immunology</i> , 2012, 188, 5839-5849.	0.8	5
24	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 95-102.	2.9	5
25	Preclinical evaluation of cancer immune therapy using patientâ€derived tumor antigenâ€specific T cells in a novel xenograft platform. <i>Clinical and Translational Immunology</i> , 2021, 10, e1246.	3.8	4
26	On the Twentieth Anniversary of Dendritic Cell Vaccines â€ Riding the Next Wave. <i>Cancer Research</i> , 2022, 82, 966-968.	0.9	4
27	Health-related quality of life in patients with malignant melanoma by stage and treatment status. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 486-489.	1.2	2
28	Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 80-80.	1.6	2
29	Use of targeted next generation sequencing (NGS) to assess mutational load in glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2027-2027.	1.6	1